Impasses and Nuances of Vaccination for COVID-19 in Children Aged 5-11 Years

F. Figueiredo, Nicoly

School of Medicine, Universidade Federal do Cariri (UFCA), Brazil.

V. Núñez, Yitzhak

School of Medicine, Universidade Federal do Cariri (UFCA), Brazil.

P. M. Pérez, Karla

School of Medicine, Universidade Federal do Cariri (UFCA), Brazil.

P. Moreira, Caroline

School of Medicine, Universidade Federal do Cariri (UFCA), Brazil.

Gonçalves Júnior, J

Hospital das Clínicas - FMUSP, Universidade de São Paulo (USP), Brazil.

L. Cândido, Estelita *

School of Medicine, Universidade Federal do Cariri (UFCA), Brazil.

*Author to whom correspondence should be addressed.


Abstract

Background: In relation to COVID-19, pediatric patients are usually asymptomatic or with mild manifestations of lesser severity. On the other hand, the literature demonstrates the reduced existence of cases that progressed to serious complications. Therefore, the release of a vaccine for this age group is extremely important for children's health and for reducing the spread of the virus. Furthermore, the immunization of children against SARS-CoV-2 was implemented in some countries and, as a result, the panorama regarding this subject has changed completely, being saturated with opinions and divergences related to the topic. In view of this, the present article aims to  clarify the nuances of SARS-Cov-2 immunization in children between the ages of 5-11 years old.

Methodology: For this study, we have conducted a review on the literature regarding vaccination against COVID-19 on the 5-11 years pediatric age group, using the MeSh terms "COVID-19", "vaccination", "children", and "pandemic", in the following databases: "Google Scholar", "PubMed" and "BVS".

Results: Overall, the research has shown that the most common side effects in the pediatric age group, when present, were local pain (48,7%), headache (20,4%), fatigue (27,7%), myalgia (11,4%), and local erythema (11,4%), whilst severe symptoms, such as myocarditis, occurred with a low incidence (0,16%).

Conclusion: Due to the absence or, if present, mild /local side effects on children, the recommendations of the main health agencies are in favor of the immunization of this age group, although, further work on the social opinion is needed in order to increase public acceptance concerning the importance and safety of vaccination against COVID-19 in children between the ages of 5-11.

Keywords: COVID-19, SARS-CoV-2, vaccine, children, pandemic, coronavirus


How to Cite

Nicoly, F. F., Yitzhak, V. N., Karla, P. M. P., Caroline, P. M., J, G. J., & Estelita, L. C. (2023). Impasses and Nuances of Vaccination for COVID-19 in Children Aged 5-11 Years. International Journal of TROPICAL DISEASE & Health, 44(1), 50–56. https://doi.org/10.9734/ijtdh/2023/v44i11382

Downloads

Download data is not yet available.

References

WHO. Who Coronavirus 2023 Dashboard; 2022. https://covid19.who.int/. Accessed 18 January 2023.

Available: https://covid19.who.int/

Andrade et al. Lethality by COVID-19 in children: an integrative review. Residência Pediátrica. 2021; 11(1).

DOI: 10.25060/residpediatr

Márquez-González et al. COVID-19 pan-demic: challenges ahead.Bol Med Hosp In-fant Mex 2020;77(5):242-251.

DOI: 10.24875/BMHIM.20000166

Jones, Terry C et al. “Estimating infec-tiousness throughout SARS-CoV-2 infec-tion course.” Science (New York, N.Y.). 2021;373,6551: eabi5273.

DOI:10.1126/science.abi5273

She J, Liu L, Liu W. Providing children with COVID-19 vaccinations is challenging due to lack of data and wide-ranging parental acceptance. Acta Paediatrica. 2022;111(1): 35-44.

DOI: 10.1111/apa.16137

Wu J, Li Q, Tarimo CS et al. COVID-19 Vaccine Hesitancy Among Chinese Popu-lation: A Large-Scale National Study. Front Immunology. 2021;(12):sp.

DOI: 10.3389/fimmu.2021.781161

Bagateli LE et al. COVID-19 vaccine hesi-tancy among parents of children and ado-lescents living in Brazil. Vaccines. 2021; 9(10): 1115.

DOI: 10.3390/vaccines9101115

Evans S et al. ‘Poison’ or ‘protection’? A mixed methods exploration of Australian parents’ COVID-19 vaccination intentions. J. Psychosom. Res. 2021;150(110626): 110626.

DOI: 10.1016/j.jpsychores.2021.110626

Yoda T, Katsuyama H. Parents’ hesitation about getting their children vaccinated against COVID-19 in Japan. Hum. Vac-cines Immunother. 2021;1–6.

DOI: 10.1080/21645515.2021.1981087

Szilagyi PG et al. Parents’ intentions and perceptions about COVID-19 vaccination for their children: Results from a national survey. Pediatrics, 2021;148(4): e2021052335.

DOI: 10.1542/peds.2021-052335

WHO. COVID-19 advice for the public: Getting vaccinated, 2022. Accessed 03 March 2022.

Availa-ble:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice.

Brasil. Ministério da Saúde. Aprovada ampliação de uso da CoronaVac para crianças e adolescentes de 6 a 17 anos, 2022. Accessed 16 February 2022.

Available:https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2022/aprovada-ampliacao-de-uso-da-vacina-coronavac-para-criancas-de-6-a-17-anos].

Lv M et al. Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: A systematic review. Vaccines. 2021;9(10):1102.

DOI: 10.3390/vaccines9101102

Han B et al. Safety, tolerability, and immu-nogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, random-ized, controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021;21(12):1645–1653.

DOI: 10.1016/S1473-3099(21)00319-4

Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vac-cine in children 5 to 11 years of age. N Engl J Med. 2022;386(1):35–46.

DOI: 10.1056/NEJMoa2116298

Dionne A et al. Association of myocar-ditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of chil-dren. JAMA cardiol, 2021;6(12):1446– 1450.

DOI: 10.1001/jamacardio.2021.3471.15

Das BB et al. Myocarditis and pericarditis following mRNA COVID-19 vaccination: What do we know so far?, Children. 2021;8(7):607.

DOI: 10.3390/children8070607.

Poussaint TY et al. Multisystem inflamma-tory-like syndrome in a child following COVID-19 mRNA vaccination. Vaccines. 2021;10(1): 43.

DOI: 10.3390/vaccines10010043

Rodriguez-Morales, Alfonso J et al. “Vac-cination of children against COVID-19: the experience in Latin America.” Annals of clinical microbiology and antimicrobials. 2022;21(1):14,

DOI:10.1186/s12941-022-00505-7

UNICEF. Children and COVID-19 vac-cines — Your questions answered, 2022. Accessed 14 December 2022.

Availa-ble:https://www.unicef.org/rosa/stories/children-and-covid-19-vaccines.

Commonwealth of Australia. Department of Health and Aged Care. ATAGI recom-mendations on COVID-19 vaccine use in children aged 6 months to <5 years, 2022. Accessed December 13 2022.

Available: https://www.health.gov.au/news/atagi-recommendations-on-covid-19-vaccine-use-in-children-aged-6-months-to.

Sam-Agudu NA et al. Children and adoles-cents in African countries should also be vaccinated for COVID-19, BMJ Global Health 2022;7:e008315.

Availble:https://doi.org/10.1016/j.jvacx.2022.100199